Organic Active Ingredients TRIZ Cases

Pre-treatment autoimmune and liver biomarker screening identifies subjects likely to benefit from lanifibranor and helps limit adverse side-effect risk.

TROP2-targeted ADCs paired with decitabine or azacitidine enhance antitumor effects in resistant cancers and reduce dose-dependent toxicity.

Divinyl sulfone modifies and crosslinks hyaluronic acid derivatives to support biocompatibility and controlled physiological interaction.

Fibrin hydrogels support a flat, wrinkle-free RPE monolayer during surgery, then degrade to limit chronic inflammation and fibrosis.

Reduced nNOS signaling in hypothalamic circuits is addressed with NO agents that restore normal sexual behavior in PCOS-like mice.

Miotic aceclidine drops constrict the pupil to improve near and distance vision, potentially reducing reliance on lenses or surgery.

These isoindolinone and piperidine derivatives target IKZF2 degradation to focus immune activity at tumor sites and limit systemic toxicity.

Severe alcohol-associated hepatitis and ACLF need options beyond corticosteroids; Compound 1 activates FXR to regulate bile acid metabolism and protect the liver.

Targeting ligands on ZIF cages direct encapsulated agents toward prostate cancer cells while limiting exposure of essential organs.

Learn how dazucorilant modulates glucocorticoid receptors to slow ALS progression and improve overall survival.

Evaporating alcohol and water create a cooling sensation in a GTN-free formulation, supporting endogenous nitric oxide production without synthetic ED actives.

After antibiotic disruption, Clostridium scindens converts primary bile acids into secondary bile acids that inhibit C. difficile growth and toxin production.

Low cellular uptake and blood instability constrain mRNA vectors; unsaturated amino acid-based cationic lipids improve membrane fusion and cellular entry.

Lumateperone targets 5-HT2A and D2 pathways to treat encephalitis-related psychiatric symptoms and reinforce the blood-brain barrier.

A cyclical azabicyclic regimen treats malignant tumors while withdrawal periods limit retinal accumulation linked to ocular toxicity.

High intracellular ATP and kinome off-targets challenge PLK inhibition; PBD-binding small molecules target PLK1 selectively.

P2RY2 modulators alter B7-H3 activity to increase T cell anti-cancer function where CTLA-4 or PD-1/PD-L1 blockade has limited response.

Combining tenofovir alafenamide and emtricitabine in a low-excipient tablet preserves stability and bioequivalence while reducing dosage burden.

This case uses a piperidinyl bipyridyl compound to reduce seizure frequency and plasma 24HC levels in epileptic encephalopathies.

Low solubility, pH-dependent gelling, and light sensitivity are addressed with binder-based spray granulation for better dissolution and absorption.

Current HCM therapies often ease symptoms without addressing sarcomere dysfunction; these compounds inhibit beta cardiac myosin to improve relaxation.

Small-molecule GLP-1R agonists address injection dependence by supporting oral bioavailability while regulating glucose and reducing food intake.

TREM2 agonists compensate for ABCD1 dysfunction by preserving microglial activity and limiting astrocytosis in X-ALD.

See how optimized AAK1 inhibitor synthesis controls impurities and harmful byproducts for safer, higher-yield scale-up.

A diminazene-derived library uses fluorescence displacement and calorimetry to identify molecules that stabilize or destabilize MALAT1 triple helices.

Peptide GLP-1 agonists improve blood glucose control but have poor oral bioavailability; fused imidazole derivatives offer an oral small-molecule approach.

Substituted oxopyridine derivatives target factor XIa to improve pharmacokinetic behavior, extend half-life, and reduce bleeding risk.

P2Y12 receptor modulation by clopidogrel and related agents targets perisynaptic Schwann cells to preserve and repair NMJs.

A single high dose of budiodarone targets sustained plasma levels to cardiovert AFib to sinus rhythm within 90 minutes.

Low water solubility limits oral efinaconazole bioavailability; a polyethylene glycol co-crystal improves dissolution and stability.

Heteroaryl compounds inhibit xanthine oxidase to lower serum uric acid, addressing toxicity and limited efficacy in existing gout treatments.

Selective dimethoxyphenylalkylamine compounds target 5-HT2A signaling and recruit β-arrestin 2 to pursue therapy with fewer hallucinogenic effects.

Limited knockdown duration and oligonucleotide stability are addressed with modified RNAi sequences that reduce LDHA activity in hepatocytes.

Measuring alpha defensin in CSF, with a cutoff above about 250 mg/L, supports EVD-associated ventriculitis diagnosis and targeted antibiotic use.

Remote acyl participation and SN2 substitution build stereospecific O5 bonds despite poor rare-sugar reactivity, enabling antigen screening.

Sequential solvent fractionation and resin chromatography isolate new dimers from I. trichantha tubers for antitumor research.

Stirring elacestrant dihydrochloride in chloroform and drying produces Form CSII with higher solubility, flowability, and stability.

Novel metal-binding compounds address inadequate conventional inhibitors by regulating metalloenzymes linked to cancer, Alzheimer's disease, and hemochromatosis.

Current treatments mainly manage symptoms; fused amino pyrimidine compounds modulate KCC2 to regulate chloride levels and neuronal inhibition.

Local delivery of an anti-SEMA4D blocking antibody limits immune cell infiltration in salivary glands while reducing systemic side effects.

A stabilized topical composition uses specific bases and excipients to keep bis-(2-chloroethyl)methylamine at 90% or more for up to 90 days.

Acid-resistant delayed release limits stomach exposure, helping preserve active (Z)-endoxifen and deliver it in the intestine.

Defined salts and solid forms, including hydrates and solvates, address variable pharmaceutical stability and bioavailability in treatment.

CRISPR/Cas editing of PKM in CHO cells reduces lactate accumulation, helping preserve cell viability, productivity, and recombinant protein quality.

Learn how CircCYB knockdown promotes apoptosis in lung cancer cells while sparing normal cells for targeted treatment.

Small-molecule compounds inhibit APOL1 to address targeted treatment gaps in APOL1-associated nephropathies and renal allograft loss.

The free acid had insufficient high-dose bioavailability; crystalline cholinate improves solubility, handling, and storage stability.

Retigabine’s efficacy and tolerability trade-off is addressed with Kv7.2/7.3 potentiators that normalize motor neuron excitability.

Specific X-ray diffraction peaks identify a monoclinic compound B crystal form that improves stability and pharmacokinetics for selective FGFR4 inhibition.

EED-binding compounds address weak PRC2 inhibitor activity against EZH2 activating mutations while improving cellular potency, stability, and safety.